Viridian Therapeutics is a biopharmaceutical company. Co. has built relevant capabilities in monoclonal antibody discovery and engineering, biologics manufacturing, and nonclinical and clinical development for thyroid eye disease (TED) and other undisclosed target indications in rare and autoimmune diseases. Co. is developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that are being developed for intravenous or subcutaneous administration to treat patients who suffer from TED. Co.'s primary program, VRDN-001, is a humanized monoclonal antibody targeting insulin-like growth factor 1 receptor intravenously administered for the treatment for TED. The VRDN YTD return is shown above.
The YTD Return on the VRDN YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether VRDN YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VRDN YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|